title: Inclusion body myositis: diagnosis, pathogenesis, and treatment options.
abstract: Inclusion body myositis (IBM) is the most common acquired myopathy in people older than 50 years. IBM typically presents with distal upper extremity weakness accompanied by proximal lower extremity muscle weakness. Associated clinical findings include asymmetric weakness, foot drop, and dysphagia. The pathogenesis of IBM is not clear. In this article the authors briefly discuss postulated pathogenic mechanisms. Although no proven pharmacotherapy exists, some promising candidates are discussed.
authors: Department of Neurology, University of Virginia School of Medicine, PO Box 800394, Charlottesville, VA 22908-0394, USA. ges3b@virginia.edu
authors: Guillermo E
authors: GE
authors: Solorzano
authors: Lawrence H
authors: LH
authors: Phillips
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003937:Diagnosis, Differential; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D018482:Muscle, Skeletal / Q000473:pathology / Q000503:physiopathology; D018979:Myositis, Inclusion Body / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D017285:Polymyositis / Q000175:diagnosis; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept